News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Recommends Commissioning Of Eculizumab (Soliris®) For All Patients With aHUS In England


9/4/2014 11:47:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the National Institute for Health and Clinical Excellence (NICE) Highly Specialised Technologies Evaluation Committee (EC) has reaffirmed the very significant clinical value of eculizumab (SolirisĀ®) for the treatment of atypical hemolytic uremic syndrome (aHUS) and the lack of other effective therapies, and has issued a recommendation that it be nationally commissioned for all patients suffering from this severe and life-threatening genetic disorder.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES